High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma
Open accessThe DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Abstract
High metabolic tumor volume (MTV) predicts worse outcomes in lymphoma treated with chemotherapy. However, it is unknown if this holds for patients treated with axicabtagene ciloleucel (axi-cel), an anti-CD19 targeted chimeric antigen receptor T-cell therapy. The primary objective of this retrospective study was to investigate the relationship between MTV and survival (overall survival [OS] and progression-free survival [PFS]) in patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axi-cel. Secondary objectives included finding the association of MTV with response rates and toxicity. The MTV values on baseline positron emission tomography of 96 patients were calculated via manual methodology using commercial software. Based on a median MTV cutoff value of 147.5 mL in the first cohort (n = 48), patients were divided into high and low MTV groups. Median follow-up for survivors was 24.98 months (range, 10.59-51.02 months). Patients with low MTV had significantly superior OS (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.10-0.66) and PFS (HR, 0.40; 95% CI, 0.18-0.89). Results were successfully validated in a second cohort of 48 patients with a median follow-up for survivors of 12.03 months (range, 0.89-25.74 months). Patients with low MTV were found to have superior OS (HR, 0.14; 95% CI, 0.05-0.42) and PFS (HR, 0.29; 95% CI, 0.12-0.69). In conclusion, baseline MTV is associated with OS and PFS in axi-cel recipients with LBCL.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that high metabolic tumor volume (MTV) is associated with a poor response to axi-cel.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [37]
In the citing paper
“High tumor burden is associated with poorer outcomes after axi-cel therapy.37,60”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [37]
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715 · cited 1×
“For ZUMA-1, tumor burden was evaluated by the SPD of bidirectional measurements in #6 reference lesions on computed tomography (CT).(5,6) Alternative methods include calculating maximum standardized uptake value (SUVmax) or baseline metabolic tumor volume (MTV) on (18)F fluorodeoxyglucose ((18)F-FDG) positron”
MethodLee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“Maximum cytokine release syndrome (CRS) was graded by Lee criteria.(15) Maximum neurotoxicity (NT) was graded by Common Terminology Criteria for Adverse Events (CTCAE) version 4.”
MethodLocke, F. L., Neelapu, S. S., Bartlett, N. L., Siddiqi, T., Chavez, J. C., Hosing, C. M., Ghobadi, A., Budde, L. E., Bot, A., Rossi, J. M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.020 · Cited by 620 · cited 1×
“Axicabtagene ciloleucel (axi-cel), a CD19 targeted chimeric antigen receptor (CAR) T-cell therapy, can successfully induce durable remissions after $2 lines of therapy.(2,3) In the pivotal ZUMA-1 trial, high tumor burden estimated by the sum of the product of diameters (SPD) was associated with lower durable response…”
BackgroundSelf-citationMeignan, M., Sasanelli, M., Casasnovas, R. O., Luminari, S., Fioroni, F., Coriani, C., Masset, H., Itti, E., Gobbi, P. G., Merli, F., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2705-y · Cited by 186 · cited 2×
“41% SUVmax were included for calculation of lesion MTV (mL), as this was demonstrated most accurate for lymphoma.(13,14) Additional details on the MTV process for automatic lesion selection are provided in supplemental Methods.”
MethodPennisi, M., Jain, T., Santomasso, B. D., Mead, E., Wudhikarn, K., Silverberg, M. L., Batlevi, Y., Shouval, R., Devlin, S. M., Batlevi, C., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000952 · Cited by 158 · cited 2×
“Additionally, we did not capture American Society for Transplantation and Cellular Therapy grading in a majority of our patients,(21) although we and others reported the high concordance of NT grade 3-4 by CTCAE and American Society for Transplantation and Cellular Therapy.(22,23)”
ResultIlyas, H., Mikhaeel, N. G., Dunn, J. T., Rahman, F., Møller, H., Smith, D., & Barrington, S. F. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3953-z · Cited by 150 · cited 1×
“41% SUVmax were included for calculation of lesion MTV (mL), as this was demonstrated most accurate for lymphoma.(13,14) Additional details on the MTV process for automatic lesion selection are provided in supplemental Methods.”
MethodGuo, B., Tan, X., Ke, Q., & Cen, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210224 · Cited by 137 · cited 1×
“It has been shown to be prognostic in nonHodgkin’s lymphoma,(9,10) with high MTV associated with worse outcomes following immunotherapy, chemotherapy, or radiation therapy.(11,12) The clinical significance of baseline tumor burden as determined by MTV in CAR T-cell treated lymphoma patients, however, remains unclear.”
BackgroundWang, J., Hu, Y., Yang, S., Wei, G., Zhao, X., Wu, W., Zhang, Y., Zhang, Y., Chen, D., Wu, Z., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.02.008 · Cited by 134 · cited 2×
“008).(18) In agreement with these studies, our results showed an association of MTV with G3-4 CRS, but not NT by CTCAE.”
MethodResultThe International Harmonization Project for Response Criteria in Lymphoma Clinical Trials
Cheson, B. D. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.06.011 · Cited by 132 · cited 1×
“For ZUMA-1, tumor burden was evaluated by the SPD of bidirectional measurements in #6 reference lesions on computed tomography (CT).(5,6) Alternative methods include calculating maximum standardized uptake value (SUVmax) or baseline metabolic tumor volume (MTV) on (18)F fluorodeoxyglucose ((18)F-FDG) positron”
Method
Cited by
Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., et al. (2021) · Blood · doi:10.1182/blood.2020007445 · Cited by 297
Self-citationStein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02234-6 · Cited by 255
Self-citationNext-Generation CAR T-cell Therapies
Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N., & June, C. H. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1683 · Cited by 179
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy
Jain, M. D., Smith, M., & Shah, N. N. (2023) · Blood · doi:10.1182/blood.2022017414 · Cited by 159
Self-citationCRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
Greenbaum, U., Strati, P., Saliba, R. M., Torres, J., Rondon, G., Nieto, Y., Hosing, C., Srour, S. A., Westin, J., Fayad, L. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004575 · Cited by 158
Metadata
- Authors
- Dean, E. A., Mhaskar, R. S., Lu, H., Mousa, M. S., Krivenko, G. S., Lazaryan, A., Bachmeier, C. A., Chavez, J. C., Nishihori, T., Davila, M. L., Khimani, F., Liu, H. D., Pinilla-Ibarz, J., Shah, B. D., Jain, M. D., Balagurunathan, Y., & Locke, F. L.
- Affiliations
- Moffitt Cancer Center (US)
- University of South Florida (US)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Department of Diagnostic Imaging and Interventional Radiology,
- Department of Blood and Marrow Transplant and Cellular Immunotherapy, and
- Department of Malignant Hematology, H. Lee Moffitt Cancer and Research Institute, Tampa, FL;
- Department of Biostatistics and Bioinformatics, and
- ORCID
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2020-07-23
- Volume
- 4
- Issue
- 14
- Pages
- 3268-3276
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC7391155
- OpenAlex
- W3044532926
- Cited by
- 256
- References
- 22
- Citations by year
- 2026: 29 · 2025: 42 · 2024: 48 · 2023: 52 · 2022: 44 · 2021: 36 · 2020: 4
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons - University of South Florida (University of South Florida) (submittedVersion)
- Funders
- National Cancer Institute (K23CA201594, P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- metabolic tumor volume, axicabtagene ciloleucel, large B-cell lymphoma, relapsed/refractory lymphoma, CAR T-cell therapy, anti-CD19, overall survival, progression-free survival, prognostic factors, positron emission tomography, treatment response, toxicity
- MeSH terms
- Biological Products, Humans, Retrospective Studies, Immunotherapy, Adoptive, Antigens, CD19, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. https://app.cochat.ai/papers/10.1182/bloodadvances.2020001900
- The paper
- Dean, E. A., Mhaskar, R. S., Lu, H., Mousa, M. S., Krivenko, G. S., Lazaryan, A., Bachmeier, C. A., Chavez, J. C., Nishihori, T., Davila, M. L., Khimani, F., Liu, H. D., Pinilla-Ibarz, J., Shah, B. D., Jain, M. D., Balagurunathan, Y., & Locke, F. L. (2020). High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. https://doi.org/10.1182/bloodadvances.2020001900
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.